臨床泌尿器科76巻6号

2022年05月発行

綜説

筋層浸潤性膀胱癌に対する周術期補助薬物治療の最前線

著者： 菊地栄次¹ 早川望¹

所属機関： ¹聖マリアンナ医科大学腎泌尿器外科学

ページ範囲：P.347 - P.353

文献概要

要旨

　筋層浸潤性膀胱癌に対する標準治療は膀胱全摘除術であるが，さらなる予後向上を目指して周術期補助治療が試みられてきた．代表的な臨床試験としてSWOG8710，VESPER，EORTC 30994，CheckMate 274，IMvigor010が挙げられる．シスプラチンベースの術後補助化学療法は，一般的に患者の忍容性が低く，また術前補助化学療法後の残存高リスク腫瘍に対する追加治療としての意義は乏しい．術後補助治療として最近，ニボルマブの使用が承認され，real-worldでの実績が試されている．今後，筋層浸潤性膀胱癌に対して手術治療と相性のよい，長期予後向上に寄与する新規周術期補助薬物治療の登場が期待される．

参考文献

1） Madersbacher S, et al : Radical Cystectomy for Bladder Cancer Today ― A Homogeneous Series without Neoadjuvant Therapy. J Clin Oncol 21 : 690-696, 2003

2） Stein JP, et al : Radical Cystectomy in the Treatment of Invasive Bladder Cancer : Long-Term Results in 1,054 Patients. J Clin Oncol 19 : 666-675, 2001

3） Grossman HB, et al : Neoadjuvant Chemotherapy Plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N Engl J Med 349 : 859-866, 2003

4） International Collaboration of Trialists : International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-invasive Bladder Cancer : Long-Term Results of the BA06 30894 Trial. J Clin Oncol 29 : 2171-2177, 2011

5） 日本泌尿器科学会 （編） : 膀胱癌診療ガイドライン2019年版. 医学図書出版, 東京, 2019

6） Witjes JA, et al : European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer : Summary of the 2020 Guidelines. Eur Urol 79 : 82-104, 2021

7） Pfister C, et al : Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints : Chemotherapy Toxicity and Pathological Responses. Eur Urol 79 : 214-221, 2021

8） Pfister C, et al : Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Nonmetastatic Muscle-Invasive Bladder Cancer : Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol, 2022 ［Online ahead of print］

9） Culine S, et al : Chemotherapy for Muscle-invasive Bladder Cancer : Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER （GETUG-AFU V05） Trial. Clin Genitourin Cancer 19 : 554-562, 2021

10） Sternberg CN, et al : Immediate versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder （EORTC 30994） : An Intergroup, Open-Label, Randomised Phase 3 Trial. Lancet Oncol 16 : 76-86, 2015

11） Patel HD, et al : Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer : Implications for Pathological Response and Survival. J Urol 207 : 77-85, 2022

12） D'Andrea D, et al : Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol 207 : 70-76, 2022

13） Veskimae E, et al : What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol 2 : 625-642, 2019

14） Sjödahl G, et al : Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol 81 : 523-532, 2022

15） Galsky MD, et al : Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol 34 : 825-832, 2016

16） Advanced Bladder Cancer Meta-analysis Collaborators Group : Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer : A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol 81 : 50-61, 2022

17） Omura M, et al : Potential Therapeutic Effects of Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Locally Advanced Muscle-Invasive Bladder Cancer. Jpn J Clin Oncol 52 : 388-396, 2022

18） Martinez Chanza N, et al : Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. Eur Urol Oncol 3 : 671-679, 2020

19） Parker WP, et al : Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy : The Role of Adjuvant Chemotherapy. Clin Genitourin Cancer, 2017 ［Online ahead of print］

20） Seisen T, et al : Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy. JAMA Oncol 4 : 225-229, 2018

21） Donat SM, et al : Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy : A High-Volume Tertiary Cancer Center Experience. Eur Urol 55 : 177-185, 2009

22） Millikan R, et al : Integrated Therapy for Locally Advanced Bladder Cancer : Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC versus Cystectomy with Both Preoperative and Postoperative M-VAC. J Clin Oncol 19 : 4005-4013, 2001

23） Bajorin DF, et al : Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 384 : 2102-2114, 2021

24） Bellmunt J, et al : Adjuvant Atezolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma （IMvigor010） : A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol 22 : 525-537, 2021

25） Kartolo A, et al : Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer : Is It Ready for Prime Time? Eur Urol 80 : 679-681, 2021

26） Powles T, et al : ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma. Nature 595 : 432-437, 2021